Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2018-06-01 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
关于获得长效重组人促卵泡激素注射液药物临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the approval of a clinical trial permit for a new drug (long-acting recombinant human follicle-stimulating hormone injection) by the National Medical Products Administration of China. It details the drug's basic information, regulatory approval status, and potential impact on the company. The document is relatively short (1795 characters) and serves as an official announcement of regulatory approval rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed financial data. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-06-01 Chinese
关于获得重组全人抗CTLA-4单克隆抗体注射液药物临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing SL Pharmaceutical Co., Ltd. regarding the approval of a clinical trial application for a recombinant human anti-CTLA-4 monoclonal antibody injection by the National Medical Products Administration. It details the drug's basic information, regulatory approval, clinical trial status, and potential impact on the company. The document is an official announcement of a regulatory approval event, not a financial report, earnings release, or management discussion. It does not contain financial data or detailed financial analysis. The document length is 1932 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2018-05-24 Chinese
关于公司部分董事、高级管理人员减持计划期限届满的公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding the expiration of a share reduction plan by certain directors and senior management of the company. It details that no shares were actually sold during the plan period and references compliance with relevant regulations. There is no financial data, earnings information, or report attached. The content focuses on insider share transactions by company directors and executives. Therefore, this document fits the category of Director's Dealing (DIRS). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2018-05-23 Chinese
2018年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2018 first extraordinary general meeting (临时股东大会) of Beijing SL Pharmaceutical Co., Ltd. It includes voting results for multiple proposals, attendance details, and legal opinions confirming the validity of the meeting and its procedures. The content focuses on shareholder voting outcomes and meeting resolutions rather than presenting financial data or management discussion. The document is not a full annual or interim report, nor is it a call transcript or capital update. It is not a proxy solicitation or remuneration report. The key feature is the official disclosure of voting results from a shareholders' meeting. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6306 characters) and detailed voting data support this classification with high confidence.
2018-05-10 Chinese
2018年第一次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the 2018 first extraordinary general meeting (EGM) of Beijing SL Pharmaceutical Co., Ltd. It details the convening, attendance, agenda, voting procedures, and results of the shareholders' meeting. The document includes verification of the legality and validity of the meeting and its resolutions. It is not a financial report, earnings release, or management discussion, but rather a formal legal opinion related to the shareholder meeting and its voting outcomes. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official voting results and validates the shareholder meeting process.
2018-05-10 Chinese
关于召开2018年度第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2018 first extraordinary general meeting (临时股东大会) of Beijing SL Pharmaceutical Co., Ltd. It includes information about the meeting time, location, voting procedures, agenda items (such as amendments to company articles and internal management systems), and proxy forms. There is no financial data, earnings information, or audit content. The document is not a report itself but a formal announcement and invitation to shareholders to attend and vote at the meeting. This fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document length (7297 characters) and content confirm it is a meeting notice and related materials, not a report publication announcement or regulatory filing. Therefore, the classification is AGM-R with high confidence.
2018-04-24 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.